NCT07217496 2026-03-17N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerUniversity of California, San FranciscoPhase 1 Withdrawn
NCT04878029 2026-01-23Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CancerEmory UniversityPhase 1 Recruiting32 enrolled